The oral on-demand treatment candidate sebetralstat for hereditary angioedema (HAE) is getting to keep its orphan drug status in the…
Articles by Patricia Inácio, PhD
Delays in administering on-demand treatment are common in hereditary angioedema (HAE), with 51% of patients receiving treatment more than…
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended that sebetralstat be approved…
A woman was diagnosed with hereditary angioedema (HAE) 20 years after her first symptoms, according to a case report…
The first patient has been dosed in a Phase 3 clinical trial testing NTLA-2002, Intellia Therapeutics’ gene-editing treatment candidate…
Astria Therapeutics is on track to start a Phase 3 clinical trial of navenibart, its therapy to prevent swelling…
Treatment with navenibart, or STAR-0215, safely reduced the rate of monthly swelling attacks by 90% to 95% in…
Stroke patients treated with alteplase, a medication used to dissolve blood clots, are at an increased risk of developing…
Orladeyo (berotralstat), an oral therapy designed to reduce or prevent hereditary angioedema (HAE) attacks, is now available in Ireland.
An 80-year-old man in Texas developed angioedema thought to be triggered by the antipsychotic therapy risperidone, according to a…